P/B
1,3
Takeda Pharmaceutical
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
$59.8B
Market Cap • 9/18/2026
1925
(101 years)
Founded
2008
(18 years ago)
IPO
NYSE
Listing Exchange
Japan
Country
Valuation
P/S
2
P/EBITDA
8,6
P/OCF
10,2
P/FCF
12,6
P/E
—
BVPS
14,6
EPS
—
Market Cap
Market Cap
59,8B
EV
86,9B
EV/Revenue
3
EV/EBITDA
12,5
EV/EBIT
32,7
Payout
Dividend Per Share
0,6
Dividend Yield
3,1%
Buyback Yield
0%
Total Yield
3,1%
Dividend Yield 5Y
3,9%
Payout
171%
Retained Earnings
4,1B
Profitability
Gross Margin
66%
EBITDA Margin
23,7%
EBIT Margin
9,1%
Net Margin
3,8%
D&A/EBITDA
65,2%
R&D/Revenue
15,2%
Capex/Revenue
3,8%
Capex/D&A
25,8%
Capex/OCF
18,9%
SBC/OCF
7,8%
% PPE
13,7%
% Goodwill
37,6%
ROE
2,3%
ROIC
2,1%
Growth
CAGR Revenue 5Y
-0,1%
CAGR Op. Income 5Y
-12,6%
CAGR Net Income 5Y
-22,1%
CAGR OCF 5Y
-8,8%
Leverage
N.D./EBITDA
3,9
Debt/Equity
0%
Current Ratio
1,1
Quick Ratio
0,5
Interest Coverage
128,6%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!